05.01.2026

Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

Key Takeaways Sun Pharma will acquire Organon in an all-cash deal valued at $11.75 billion, significantly expanding its global scale and product portfolio The combined company will strengthen its position in women’s health, branded generics, and biosimilars, while increasing its focus on innovative medicines The transaction, expected to close in early 2027, is projected to boost revenue, nearly double EBITDA and cash flow, and enhance long-term growth potential Sun Pharmaceutical and Organon announced a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14 per share in cash, valuing the transaction at an enterprise value of approximately $11.75 billion. The deal marks a significant strategic expansion for Sun Pharma, positioning the Indian drugmaker as a more diversified global pharmaceutical player with a stronger foothold in women’s health, biosimilars, and branded generics.